Respiration International Journal of Thoracic Medicine - Pneumology Immunology and Allergy - Karger Publishers
←
→
Transkription von Seiteninhalten
Wenn Ihr Browser die Seite nicht korrekt rendert, bitte, lesen Sie den Inhalt der Seite unten
99 | 04 | 20
Pneumology
Immunology
and Allergy
Respiration
International Journal of
Thoracic Medicine
EABIP
OFEV®
(Nintedanib)
WIRKT RISIKO LANGZEIT- EINFACH
DATEN
der jährlichen Risikoreduktion bei bestätigen die Einfache Einnahme
Abnahme der adjudizierten*, akuten Resultate aus den 1 Kapsel
Lungenfunktion Exazerbationen Zulassungsstudien 2x täglich1,2
(FVC -49%)1,2 bei (-68%)1,2 sowie und zeigen keine
einem breiten on-treatment neuen sicherheits-
Patientenspektrum3-5 Mortalität (-43%)6 relevanten Aspekte
entgegen gepoolte Daten aus 3 Studien (n= 734, Median 44,7
(HR 0.57 [95% CI: 0.34, 0.97]; Monate, 11,9-68,3)7
p=0.0274)
*) Bewertung durch ein unabhängiges Expertengremium
1.) OFEV® Fachinformation, www.swissmedicinfo.ch 2.) Richeldi L et al. Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis. NEJM 2014; 370:2071-2082 3.) Kolb M. et al.
Nintedanib in patients with idiopathic pulmonary fibrosis and preserved lung volume. Thorax 2016; 0:1-7 4.) Raghu G et al. Effects of Nintedanib in Subgroups of Idiopathic Pulmonary
Fibrosis by Diagnostic Criteria. Am J Respir Crit Care Med. 2017;195:78-85 5.) Cottin V et al.Therapeutic effects of nintedanib are not influenced by emphysema in the INPULSIS trials.
ERS 2019 6.) Richeldi L et al. Nintedanib in patients with idiopathic pulmonary fibrosis: Combined evidence from the TOMORROW and INPULSIS® trials. Resp Med 113 (2016) 74-79
7.) Crestani B et al. Long-term safety and tolerability of nintedanib in patients with idiopathic pulmonary fibrosis: results from the open-label extension study INPULSIS-ON. Lancet
Respir Med. 2018;doii:10.1016/S2213-2600(18)30339-4
Ofev®: Nintedanibesilat (Tyrosinkinaseinhibitor). I: Behandlung der idiopathischen Lungenfibrose (IPF) und Verlangsamung des Krankheitsverlaufes. D: Empfohlene Dosis: 150 mg 2x
pro Tag im Abstand von etwa 12 Stunden. KI: Schwangerschaft, Überempfindlichkeit gegen Nintedanib oder einen der sonstigen Bestandteile, Erdnüsse, Soja. VM: Eingeschränkte
Leberfunktion, Child-Pugh B,C: Anwendung nicht empfohlen. Child-Pugh A: Empfohlene Dosis 100 mg 2x pro Tag. Es wurden nicht-schwerwiegende und schwerwiegende (auch fatale)
arzneimittelinduzierte Leberschäden beobachtet. Hepatische Transaminasen, Bilirubinwerte zu Beginn und regelmässig in den ersten drei Monaten und danach periodisch kontrollieren.
Falls trotz symptomatischer Therapie von Diarrhö, Übelkeit, Erbrechen keine Besserung eintritt oder bei Transaminasenanstieg auf das 3-fache der Obergrenze des Normbereiches,
sollte die Dosis auf 100 mg 2x pro Tag reduziert oder die Behandlung abgebrochen werden. Endgültiges Absetzen der Behandlung bei klinischen Zeichen einer Leberschädigung
(Gelbsucht) oder bei Transaminasenanstieg > 5-fache Obergrenze des Normbereichs. Diarrhö und Erbrechen kann zur Dehydrierung mit oder ohne Elektrolytstörungen führen. Fälle
D-012020-PC-CH-100948 Respiratory OFEV
von Nierenfunktionsstörungen bzw. Nierenversagen, auch fatale, wurden berichtet. Patienten mit Risikofaktoren für Nierenfunktionsstörungen sollten überwacht werden. Anpassung
der Therapie bei Nierenfunktionsstörung. Bei Patienten mit Antikoagulation, erhöhtem kardiovaskulären Risiko, Hypertonie oder Aneurysmen in der Vorgeschichte, arteriellen
thromboembolischen Ereignissen, venöser Thromboembolie und Wundheilungsstörungen sollte Nintedanib mit Vorsicht angewendet werden. Fälle von schwerwiegenden und tödlichen
Blutungen (Patienten mit/ohne Antikoagulanzien oder anderen Arzneimitteln, die Blutungen hervorrufen könnten) und Fälle von gastrointestinalen, auch tödlichen Perforationen,
wurden berichtet. Bei Patienten mit kürzlichem bauchchirurgischem Eingriff, kürzlich aufgetretener Perforation eines Hohlorgans, peptischen Ulzera in der Anamnese, Divertikulose
oder einer begleitenden Anwendung von Corticosteroiden oder NSAR ist besondere Vorsicht geboten. Endgültiges Absetzen der Behandlung bei Auftreten einer gastrointestinalen
Perforation. Bei Befunden oder Symptomen einer akuten Myokardischämie ist eine Unterbrechung der Behandlung in Betracht zu ziehen. S: Nintedanib in der Schwangerschaft nicht
anwenden, Stillen unterbrechen. Adäquate Kontrazeption UW: Sehr häufig: Diarrhö, Übelkeit, Abdominalschmerz, erhöhte Leberenzyme. Häufig: Appetitverlust, Gewichtsverlust,
Erbrechen, Blutungen (Hämatochezie, Nasenbluten, Bluterguss; tödliche Ereignisse: gastrointestinale, intrakranielle, pulmonale Blutungen, DIC), erhöhte Leberenzymwerte (ALT, AST,
GGT), Hautausschlag. Gelegentlich: Hypertonie (inkl. hypertensive Krise und hypertensive Kardiomyopathie), Thrombozytopenie, Erhöhung der Alkalischen Phosphatase im Blut,
Hyperbilirubinämie, arzneimittelbedingter Leberschaden, Pankreatitis, gastrointestinale Perforation, Colitis, Pruritus IA: Starke P-gp-Inhibitoren (Ketoconazol, Erythromycin) können
die Nintedanib-Exposition erhöhen. Starke P-gp-Induktoren (Rifampicin, Carbamazepin, Phenytoin, Johanniskraut) können die Nintedanib-Exposition verringern. Die Nintedanib-
Exposition nahm unter Pirfenidon ab, Nintedanib beeinflusste nichte die Pirfenidon-Exposition. Nintedanib mit Nahrung einnehmen. P: Kapseln zu 100mg und 150mg: 60. Liste B.
Kassenzulässig. Stand der Information: Oktober 2019; vollständige Fachinformation auf www.swissmedicinfo.ch. Boehringer Ingelheim (Schweiz) GmbH, Hochbergerstrasse 60B,
Postfach, 4002 Basel.
Boehringer Ingelheim (Schweiz) GmbH
F20504
Hochbergerstrasse 60B, CH-4002 Basel, Telefon 061 295 25 25
MEDinfoIPF.BAS@boehringer-ingelheim.ch
Official Journal of
Respiration
International Journal of Thoracic Medicine
Founded 1944 as “Schweizerische Zeitschrift für Tuberkulose und
EABIP Pneumonologie” by E. Bachmann, M. Gilbert, F. Häberlin, W. Löffler,
P. Steiner and E. Uehlinger, continued 1962–1967 as “Medicina Thoracalis”,
as of 1968 as “Respiration”, H. Herzog (1962–1997), C.T. Bolliger (1998–2012)
Editor-in-Chief
Felix J.F. Herth – Universitätsklinikum Heidelberg, Heidelberg, Germany
Associate Editors
Konrad E. Bloch – Universitätsspital Zürich, Zurich, Switzerland
Annette Boehler – Universitätsspital Zürich, Zurich, Switzerland
Demosthenes Bouros – University of Athens, Athens, Greece
Alfredo Chetta – Università degli Studi di Parma, Parma, Italy
Vincent Cottin – Hôpital Louis Pradel, Lyon, France
Christophe Dooms – University Hospitals Leuven, Leuven, Belgium
Ernst Eber – Medical University of Graz, Graz, Austria
Stefano Gasparini – Ospedale Torrette, Ancona, Italy
Jürg Hammer – University Children’s Hospital Basel, Basel, Switzerland
Coenraad F. Koegelenberg – University of Stellenbosch, Tygerberg Cape Town,
South Africa
Christoph Lange – German Center for Infection, Borstel, Germany
Marek Lommatsch – Universität Rostock, Rostock, Germany
Marc Miravitlles – Hospital Universitari Vall d’Hebron, Barcelona, Spain
Joachim Müller-Quernheim – Universitätsklinikum Freiburg, Freiburg, Germany
Laurent P. Nicod – Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
Dario Olivieri – University of Parma, Parma, Italy
Venerino Poletti – Ospedale G.B. Morgagni, Forlì, Italy
Winfried J. Randerath – Krankenhaus Bethanien, Solingen, Germany
Otto D. Schoch – Kantonsspital St. Gallen, St. Gallen, Switzerland
Esther Irene Schwarz – Sleep Disorders Centre at Guy’s & St Thomas’ NHS Foundation
Trust, London, UK
Pallav L. Shah – Imperial College London, London, UK
Dirk-Jan Slebos – University Medical Center, Groningen, The Netherlands
Silvia Ulrich – Universitätsspital Zürich, Zurich, Switzerland
Omar S. Usmani – National Heart and Lung Institute & Royal Brompton Hospital,
London, UK
Stephan F. van Eeden – University of British Columbia, Vancouver, BC, Canada
Lowie Vanfleteren – Gothenburg University, Gothenburg, Sweden
Kazuhiro Yasufuku – University of Toronto, Toronto, ON, Canada
(Continued on next page)
Printed in Switzerland on acid-free and non-aging paper
(ISO 9706) by Werner Druck & Medien AG, Basel
(Continued)
Editorial Board Members
Xavier Basagne Flores – Centre for Research in Environmental Epidemiology, Barcelona,
Spain (Statistical Consultant)
Semra Bilaceroglu – Izmir Training and Research Hospital for Thoracic Medicine and
Surgery, Izmir, Turkey
Ivan Caviedes – Clínica Alemana de Santiago, Santiago, Chile
Mario Cazzola – University of Rome, Rome, Italy
Prashant N. Chhajed – Institute of Pulmonology Mumbai, Mumbai, India
Ulrich Costabel – Ruhrlandklinik, Essen, Germany
Claudia Crimi – Azienda Ospedaliero-Universitaria Policlinico Vittorio Emanuele
di Catania, Catania, Italy
Jonne Doorduin – Radboud University Med. Center, Nijmegen, The Netherlands
Herve Dutau – Hôpital Nord, Marseille, France
Sebastian Fernandez-Bussy – Clinica Alemana de Santiago, Vitacura,
Santiago de Chile, Chile
Marios E. Froudarakis – University Hospital of Alexandroupolis, Alexandroupolis, Greece
Gerhard Hoheisel – Praxis für Pneumologie und Allergologie, Leipzig, Germany
Marc Humbert – Université Paris-Sud 11, Clamart, France
Gabriel Izbicki – Shaare Zedek Medical Center, Jerusalem, Israel
Michael Kreuter – University of Heidelberg, Heidelberg, Germany
Shiyue Li – Guangzhou Institute of Respiratory Diseases, Guangzhou, China
Weimin Li – West China Hospital of Sichuan University, Chengdu, China
Andrew R.L. Medford – University of Bristol, Bristol, UK
Nakajiama Takahiro – Chiba University, Chiba, Japan
Claudia Ravaglia – Ospedale G.B. Morgagni, Forlì, Italy
Raffaele Scala – Azienda Usl Toscana sud est, P.O. San Donato, Arezzo, Italy
Frank C. Sciurba – University of Pittsburgh, Pittsburg, PA, USA
Jiayuan Sun – Shanghai Jiao Tong University, Shanghai, China
Sara Tomassetti – Azienda Ospedaliero Universitaria Careggi, Florence, Italy
Adriano Vaghi – ASST Rhodense P.O. di Garbagnate Milanese, Milan, Italy
Claudia Valenzuela – Hospital Universitario de la Princesa, Madrid, Spain
Arschang Valipour – Otto-Wagner-Hospital, Vienna, Austria
Chen Wang – China-Japan Friendship Hospital, Beijing, China
Hubert Wirtz – Universität Leipzig, Leipzig, Germany
Emiel F.M. Wouters – University Hospital Maastricht, Maastricht, The Netherlands
© 2020 S. Karger AG, Basel
www.karger.com
karger@karger.com
Journal Information
Aims and Scope
Respiration brings together the results of both clinical and experimental investigations on all
aspects of the respiratory system in health and disease. Clinical improvements in the diag-
nosis and treatment of chest and lung diseases are covered, as are the latest findings in
physiology, biochemistry, pathology, immunology and pharmacology. The journal includes
classic features such as editorials that accompany original articles in clinical and basic science
Guidelines for Authors research, reviews and letters to the editor. Further sections are: The Eye Catcher, What’s Your
We strongly encourage authors to read
the Guidelines for Authors at
Diagnosis?, New Insights from Clinical Practice, and Guidelines.
www.karger.com/res_guidelines prior to Respiration is the official journal of the Swiss Respiratory Society (SGP) and also home to the
submitting an article. European Association for Bronchology and Interventional Pulmonology (EABIP), which oc-
cupies a dedicated section on Interventional Pulmonology in the journal. This modern mix
of different features and a stringent peer-review process by a dedicated editorial board make
Respiration a complete guide to progress in thoracic medicine.
Journal Contact
For questions or comments, please contact
the persons responsible who can be found at
http://www.karger.com/Journal/Contact/224278.
ISSN Print Edition: 0025–7931 Subscription Orders: Subscription Rates: Subscriptions run for a full
ISSN Online Edition: 1423–0356 Orders can be placed at agencies, bookstores, calendar year. Prices are given per year.
or directly with the Publisher.
Journal Homepage: www.karger.com/res Personal subscription:
Bibliographic Indices: This journal is regularly l isted S. Karger AG
Print or Online Print+Online combined
in bibliographic services, including Current Con- Medical and Scientific Publishers
CHF 590.00 CHF 679.00
tents® and PubMed/MEDLINE. Allschwilerstrasse 10
EUR 532.00 EUR 612.00
CH–4009 Basel
USD 621.00 USD 714.00
Publication Data: Respiration is published 12 times Switzerland
a year. Volume 99, with 12 issues, appears in 2020. postage and handling
t: +41 61 306 11 11
(added to print and print+online)
f: +41 61 306 12 34
Copyright: © 2020 S. Karger AG, Basel (Switzerland). CHF 105.60 Europe, CHF 148.80 Overseas
e: karger@karger.com
All rights reserved. No part of this publication may be EUR 96.00
w: www.karger.com
translated into other languages, reproduced or uti- USD 144.00
lized in any form or by any means, electronic or me- (for courier services only:
chanical, including photocopying, recording, micro- Allschwilerstrasse 10 Institutional subscription:
copying, or by any information storage and retrieval CH–4055 Basel)
Print or Online Print+Online combined
system, without permission in writing from the pub-
CHF 3456.00 CHF 3974.00
lisher. Change of Address:
EUR 3114.00 EUR 3581.00
Both old and new addresses should be sent
USD 3638.00 USD 4184.00
Disclaimer: The statements, opinions and data con- to the subscription source.
tained in this publication are solely those of the indi- postage and handling
vidual authors and contributors and not of the pub- (added to print and print+online)
lisher and the editor(s). The appearance of advertise- CHF 132.00 Europe, CHF 186.00 Overseas
ments in the journal is not a warranty, endorsement, EUR 120.00
or approval of the products or services advertised or USD 180.00
of their effectiveness, quality or safety. The publisher
and the editor(s) disclaim responsibility for any injury Back Volumes and Single Issues: Information on
to persons or property resulting from any ideas, availability and prices of single print issues and print
methods, instructions or products referred to in the or electronic back volumes can be obtained from
content or advertisements. Customer Service at service@karger.com.
© 2020 S. Karger AG, Basel
www.karger.com
karger@karger.com
Vol. 99, No. 4, 2020
Contents
Thematic Review Series
277 Navigation Bronchoscopy
Kemp, S.V. (London)
Editorial Comment
287 Presenting the Board of Respiration: Annette Boehler
Boehler, A. (Zurich)
Clinical Investigations
289 Pulmonary Rehabilitation in Patients with Pulmonary Sarcoidosis:
Impact on Exercise Capacity and Fatigue
Grongstad, A. (Jessheim/Oslo); Spruit, M.A. (Horn/Maastricht/Diepenbeek); Oldervoll, L.M.
(Trondheim); Vøllestad, N.K. (Oslo); Edvardsen, A. (Jessheim)
298 Accelerated Loss of Antigravity Muscles Is Associated with Mortality in Patients with
COPD
Tanimura, K.; Sato, S.; Sato, A.; Tanabe, N.; Hasegawa, K.; Uemasu, K.; Hamakawa, Y.; Oguma, T. (Kyoto);
Muro, S. (Kyoto/Nara); Hirai, T. (Kyoto)
307 PRDM15 Is Associated with Risk of Chronic Obstructive Pulmonary Disease in a Rural
Population in Chile
Hosgood III, H.D. (Bronx, NY); Díaz-Peña, R. (Talca); Blansky, D. (Bronx, NY); Jaime, S.; Parra, V.
(Talca); Boekstegers, F.; Bermejo, J.L. (Heidelberg); García-Valero, J.; Montes, J.F. (Barcelona); Valdivia, G.
(Santiago); Miravitlles, M.; Agustí, À. (Barcelona/Madrid); Silva, R.S.; Olloquequi, J. (Talca)
316 Cardiorespiratory Fitness and Physical Activity following Lung Transplantation:
A National Cohort Study
Ulvestad, M.; Durheim, M.T.; Kongerud, J.S. (Oslo); Hansen, B.H. (Kristiansand); Lund, M.B.;
Edvardsen, E. (Oslo)
Interventional Pulmonology
325 Is Bigger Really Better? Comparison of Ultraportable Handheld Ultrasound with
Standard Point-of-Care Ultrasound for Evaluating Safe Site Identification and Image
Quality prior to Pleurocentesis
Newhouse, S.M.; Effing, T.W.; Dougherty, B.D.; D’Costa, J.A.; Rose, A.R. (Bedford Park, SA)
333 Efficacy and Safety of the 9-mm Intrabronchial Valve in Patients with Advanced
Emphysema
Kontogianni, K.; Gompelmann, D. (Heidelberg); Valipour, A. (Vienna); Gerovasili, V. (Birmingham);
Schuhmann, M. (Heidelberg); Stanzel, F. (Hemer); Herth, F.J.F.; Eberhardt, R. (Heidelberg)
© 2020 S. Karger AG, Basel
Access to full text and tables of contents,
including tentative ones for forthcoming issues:
www.karger.com/res
344 Impact of Silicone Stent Placement in Symptomatic Airway Obstruction due to
Non-Small Cell Lung Cancer – A French Multicenter Randomized Controlled Study:
The SPOC Trial
Dutau, H. (Marseille); Di Palma, F.; Thibout, Y. (Saint Etienne); Febvre, M. (Paris); Cellerin, L.; Naudin, F.
(Nantes); Hermant, C. (Toulouse); Vallerand, H. (Reims); Lachkar, S. (Rouen); Fournier, C. (Lille);
Laroumagne, S. (Marseille); Quiot, J.-J. (Brest); Vergnon, J.-M. (Saint Etienne)
353 Safety and Efficacy of the Tracheobronchial Bonastent: A Single-Center Case Series
Holden, V.K. (Boston, MA/Baltimore, MD); Ospina-Delgado, D.; Chee, A.; Parikh, M.S.; Carreiro, M.M.
(Boston, MA); Alape Moya, D. (Boston, MA/Worcester, MA); Fernandez-Bussy, S. (Jacksonville, FL);
Herth, F.J.F. (Heidelberg); Majid, A. (Boston, MA)
Guidelines
360 Consensus-Based Care Recommendations for Pulmonologists Treating Adults with
Myotonic Dystrophy Type 1
Boentert, M. (Münster); Cao, M. (Stanford, CA); Mass, D. (Nijmegen); De Mattia, E.; Falcier, E. (Milan);
Goncalves, M. (São João); Holland, V. (Houston, TX); Katz, S.L. (Ottawa, ON); Orlikowski, D. (Garches);
Sannicolò, G. (Milan); Wijkstra, P. (Groningen); Hellerstein, L. (San Francisco, CA); Sansone, V.A. (Milan)
© 2020 S. Karger AG, Basel
Access to full text and tables of contents,
including tentative ones for forthcoming issues:
www.karger.com/res
Fasenra® est indiqué comme traitement d’entretien additionnel chez les adultes atteints d’un asthme éosinophilique sévère insuffisamment
contrôlé malgré des corticostéroïdes inhalés plus bêta-agonistes à action prolongée à haute dose1
(Benralizumab) Injektion
Subkutane
30 mg
PUISSANT
RÉDUIT LE NOMBRE D’EXACERBATIONS *
,1
PLUS DE SOUFFLE QUATRE SEMAINES SEULEMENT APRÈS LA PREMIÈRE DOSE**
,2
Le seul anticorps du récepteur de l’IL5 avec une déplétion presque totale des
éosinophiles dans le sang en 24 heures3,4
Vous trouverez l’indication détaillée dans l’information professionnelle de Fasenra®
* Réduction significative des exacerbations dans toutes les études pivots (SCIROCCO (p < 0.001), CALIMA (p < 0.019) und ZONDA (p < 0.001))
** VEMS pré-bronchodilatateur par rapport à la valeur de référence après 4 semaines dans le sous-groupe des patients présentant un taux sanguin d’éosinophiles ≥300/μl (p < 0,05). L’amélioration du VEMS à 4 semaines n’était pas un critère
d’évaluation de l’étude SIROCCO.
Références: 1. Information professionnelle, www.swissmedic.ch. 2. Bleecker ER et al. Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β2-agonists
F20509
(SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial. Lancet 2016; 388: 2115–2127. 3. Tan LD et al. Benralizumab: a unique IL-5 inhibitor for severe asthma. Journal of Asthma and Allergy 2016:9 71–81. 4. Bagnasco D et
al. Anti-Interleukin 5 (IL-5) and IL-5Ra Biological Drugs: Efficacy, Safety, and Future Perspectives in Severe Eosinophilic Asthma; Front Med (Lausanne). 2017; 4: 135. Published online 2017 Aug 31.
Fasenra®, solution pour injection sous-cutanée
C: Benralizumab, 1 ml à 30 mg; liste B. I: Adjuvant à la thérapie d’entretien chez le patient adulte à partir de 18 ans avec asthme à éosinophiles sévère caractérisé par les critères suivants: au moins deux exacerbations au cours des 12 derniers
mois sous thérapie standard actuelle (corticothérapie inhalée à hautes doses plus bronchodilatateurs de longue durée d’action) et/ou nécessité d’un traitement par corticostéroïdes systémiques; numération des éosinophiles sanguins
CH-1641_05/2019
≥ 0,3 G/litre (correspond à ≥ 300 cellules/μl). P: 30 mg par voie sous-cutanée toutes les 4 semaines, à partir de la semaine 8: 30 mg par voie sous-cutanée toutes les 8 semaines. CI: Hypersensibilité.
PR: exacerbations aiguës de l’asthme, l’arrêt brutal des corticostéroïdes est déconseillé, il convient de traiter les patients atteints d’infestations helminthiques avant l’instauration du traitement.
IA: Aucune. EI: Fréquents: céphalées, pharyngite, fièvre, réactions au site d’injection, réactions d’hypersensibilité. Occasionnel, rare, très rare: voir sous www.swissmedicinfo.ch. Mise à jour de l’infor-
mation: mars 2019. Pour plus d’informations: www.swissmedicinfo.ch ou AstraZeneca AG, Neuhofstrasse 34, 6340 Baar. www.astrazeneca.ch.
know what
matters in
Pneumology
karger.com/pneumology
KI20167_pneu_28028th Annual Meeting
German Sleep Society (DGSM)
SLEEP AND WORK
F20107
© 65464521 | lunaundmo | stock.adobe.com
29–31 October 2020 I Essen
the early bird catches the worm
Abstractdeadline: 15 May 2020 I www.dgsm-kongress.deThe interdisciplinary “hub” for researchers, clinicians
and public health professionals
www.biomedicinehub.com
An international Editorial Board • open access
with more than 170 renowned
specialists guarantees high-quality • peer-reviewed
and relevant content. • fast online publication
There is currently no Biomedicine Hub is an interdisciplinary journal: a ‘hub’ for researchers,
clinicians and public health professionals across biomedical disciplines
Article Processing Charge to share research findings, ideas, theories, experimental results and
(APC). clinical experience.
Biomedicine Hub aims at facilitating the exchange of knowledge be-
tween disciplines, with a focus on translational science for the devel-
opment of cutting-edge technologies and the improvement of health
care. A further focus is on emerging interdisciplinary fields at the fore-
front of medicine.
Biomedicine Hub
Founded: 2015
Category: Basic, Translational and Clinical Research
Fields of Interest: All
Listed in bibliographic services, including: Google Scholar
2019: Vol. 4
online only
KF 19007
Language: English More information at
e-ISSN 2296–6870 w w w. biomedicinehub.comFast Facts – The ultimate medical handbook series
John Harrington
Fast Facts:
Asthma for Patients and
Their Supporters
Harrington, J. (New Lambton Heights, NSW) Asthma is a long-term condition that reduces the amount of air
Fast Facts: Asthma for Patients
and Their Supporters
flowing in and out of the lungs. Whether your symptoms are mild,
48 p., 23 fig., 23 in color, 8 tab., 2020 difficult-to-control or severe, it is important to be in control of your
CHF 10.00 / EUR 7.00 / USD 9.00 asthma. The information in this booklet is designed to help you
Soft cover or online prices for personal
customers
and your family better understand the condition, what triggers it
Prices subject to change, VAT not included and how to treat it. It includes clear instructions for good inhaler
EUR price for eurozone countries, technique and emphasizes the importance of having an Asthma
USD price for USA and Latin America only
ISBN 978–1–912776–64–1
Action Plan in place so that you know:
e-ISBN 978–1–912776–65–8
• when and how often to take your treatment
• how to tell if your symptoms are getting worse
• what to do when your symptoms get worse.
With simple clear illustrations, explanation of medical terms and
space to write down the questions you want to ask your doctor or
nurse, this resource will help you take control of your asthma.
Contents
• What is asthma?
• What causes asthma?
• What are the symptoms of asthma?
• What are the tests for asthma?
• What medications are used to treat asthma?
• Inhalers and spacers
• Your Asthma Action Plan
• How do I prevent an asthma attack?
• How do I manage an asthma attack?
• Difficult-to-control asthma
Dear Librarian • Severe asthma
I have reviewed this publication and • Treatment of severe asthma
would like to recommend it for our library.
• Exercise-induced asthma
Recommended by: • Occupational asthma
• Asthma in older people
• Asthma in pregnancy
• Asthma in children
Department:
Date:
Signature: The easiest way to order: w w w.karger.com/fast fac ts
KI20162
Karger – Medical and Scientific Publishers
Orders may be placed with any bookshop, CH–4009 Basel, Switzerland
subscription agency, directly with the publisher orders@karger.com, f: +41 61 306 12 34
or through a Karger representative. www.karger.comSie können auch lesen
